HIV

A CD4 count of 38 and a five-day-old TB diagnosis put the team on a clock most trial evidence has already read for this exact number -- the disagreement is about how much lead time his lungs deserve first.

For most opportunistic infections, earlier antiretroviral therapy saves lives. Cryptococcal meningitis is the one place a randomized trial found the opposite, and the team has to decide how literally to read it.

The same ART-timing question that argues for waiting in cryptococcal meningitis argues for moving quickly here — a direct, deliberate contrast built on the same underlying trial logic landing in opposite places.

A viral load of 720,000 sits well past the exact number that kept patients like him out of the trial establishing two-drug ART as a first-line option — the question is how much that exclusion should actually govern his regimen.

A decade of perfect suppression argues for trusting her with a simpler regimen. A resistance test from the very beginning of that decade argues the opposite, and neither fact cancels the other out.

His oral PrEP keeps lapsing for the same reason most people's does — daily life gets in the way — and an injection every two months promises to remove that problem. It also introduces a different one, further out, that daily pills never carried.

A needlestick with visible blood and an unknown source isn't the borderline case the old two-drug-versus-three-drug debate was built for — the real question tonight is whether sixty hours is still soon enough to matter.

Twenty years of tolerated side effects is its own kind of evidence that something should change — the complication is that the one record that would make the switch straightforward predates his clinic's electronic chart by a decade.

Three genuinely novel agents, each active by a different mechanism than the resistance sitting in his chart, and no head-to-head trial to settle which combination actually fits a patient whose treatment history predates all three of them.

The dolutegravir-pregnancy controversy that once made headlines has moved substantially since 2018 — the harder question now is how much residual caution five weeks of gestation still deserves, not whether the original alarm was fully justified.

Every statin option interacts with ritonavir to some degree — the real decision is which interaction is most predictable and most manageable, not which one to pretend doesn't exist.

His CD4 count clears the discontinuation threshold today, comfortably. Whether it has done so for the length of time the guideline actually asks for depends on how one dip four months ago gets read.

Seventeen years without a single antiretroviral dose and an undetectable viral load the whole time is either a reason to leave well enough alone, or exactly the kind of unusual biology the team can't yet fully explain — and that uncertainty cuts both ways.

Everyone in the room agrees the inflammation is real and worsening. What's contested is whether treating it around a continued, working antiretroviral regimen is still the safer path, or whether his imaging has already crossed into territory that argues for pulling ART back.

His declining kidney function makes his current regimen a poor long-term fit — but each realistic alternative carries a different organ-specific risk of its own, and neither is clearly the safer trade.

Every day of delay plausibly lets the viral reservoir seed further and gives him more time to disengage from care before treatment starts — the counterargument is that treating blind, before knowing his resistance profile, carries its own real cost.

Both options in front of her are genuinely excellent by historical PrEP standards — the real disagreement is whether the newer drug's larger efficacy number should outweigh the older one's much longer track record, and whether either question matters as much as what her insurance will actually cover.